Introduction The Gastrointestinal (GI) Diseases Drug Development Market is experiencing rapid transformation, driven by advancements in biotechnology, personalized medicine, and increasing prevalence of digestive disorders worldwide. Conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), peptic ulcers, and...